1st Quarter - Report
PODESTA GROUP, INC. for AMGEN
Firm
Client
Income
$60,000
Expenses
—
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Prescription Drug User Fee Act reauthorization. FY 2013 funding regarding the FDA.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| ANTHONY PODESTA | — |
Economics/Economic Development ECN
Economic policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| ANTHONY PODESTA | — |
Health Issues HCR
Prescription Drug User Fee Act reauthorization. Biosimilar products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| ANTHONY PODESTA | — |
Medicare/Medicaid MMM
Medicare Part B reimbursement and coverage of dialysis products.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SHARON COHEN | — |
| ANTHONY PODESTA | — |
| OSCAR RAMIREZ | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.